中科生物(01237.HK)斥875萬人幣收購福建漳平農村商業銀行1%股權
中科生物(01237.HK)公佈,其間接全資附屬福建省漳平木村林產以代價875萬元人民幣(下同),向漳平市宏生礦業收購目標公司福建漳平農村商業銀行約1.03%的股權。
公司指出,目標公司約1.03%股權的相應資產淨值約爲1,247萬元,而代價較之折讓約29.84%。
目標公司經營範圍包括吸收公衆存款;發放短期、中期和長期貸款;辦理內地結算;辦理票據承兌與貼現;代理髮行、兌付及承銷政府債券;買賣政府債券、買賣和發行金融債券;同業拆借;銀行卡業務;代理收付款項及代理保險業務;及經中國銀保監會或其他相關監管機構批準的其他金融業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.